LPAR5 as a Radioligand Therapy Target
LPAR5, lysophosphatidic acid receptor 5, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, LPAR5 staining is highest in thyroid cancer (100% of samples positive), colorectal cancer (100% of samples positive) and head and neck cancer (100% of samples positive). Evidence on whether LPAR5 internalizes is mixed. Clinical status: Discovery-stage (no clinical drug program).
Is LPAR5 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in thyroid cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
LPAR5 expression in cancer
Protein expression of LPAR5 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Thyroid Cancer | 0.75 | High | 100% |
| Colorectal Cancer | 0.69 | High | 100% |
| Head and Neck Cancer | 0.67 | High | 100% |
| Gastric Cancer | 0.64 | High | 100% |
| Liver Cancer | 0.63 | High | 100% |
| Ovarian Cancer | 0.62 | High | 100% |
| Breast Cancer | 0.61 | High | 100% |
| Testicular Cancer | 0.61 | High | 100% |
| Endometrial Cancer | 0.61 | High | 100% |
| Glioma | 0.60 | High | 100% |
| Cervical Cancer | 0.56 | High | 100% |
| Pancreatic Cancer | 0.56 | High | 100% |
| Bladder Cancer | 0.52 | High | 91% |
| Neuroendocrine Tumors | 0.50 | Medium | 75% |
| Melanoma | 0.47 | Medium | 100% |
| Kidney Cancer | 0.47 | Medium | 100% |
| Lung Cancer | 0.42 | Medium | 82% |
| Skin Cancer | 0.39 | Medium | 67% |
| Prostate Cancer | 0.38 | Medium | 75% |
| Lymphoma | 0.33 | Medium | 58% |
Is LPAR5 internalized?
Uncertain. Insufficient literature found.
LPAR5 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for LPAR5 yet. Search ClinicalTrials.gov for LPAR5 trials.
LPAR5 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See LPAR5 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
LPAR5 gene essentiality (DepMap)
CRISPR knockout effect across 1255 cancer cell lines: -0.06 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related thyroid cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EPCAM · SSTR2 · EGFR · ITGAV · STEAP2 · FAP
See all radioligand therapy targets in thyroid cancer.
See how LPAR5 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.